Skip to main content
OpenTrials
Completed

NCT Number: NCT06348485

Massive Nasal Bleeding in Patients With NPC Received Curative RT

To investigate the incidence, predictive markers, and survival impact of massive nasal bleeding in nasopharyngeal carcinoma (NPC) patients who received curative radiotherapy (RT) with/without chemotherapy. A total of 1327 patients with previously untreated, biopsy-proven NPC, and no distant metastasis were retrospective reviewed. Investigators analyzed the occurrence rates of massive nasal bleeding between different characteristics and tried to identify important predictive factors. Investigators compared overall survival between patients with and without massive nasal bleeding by Kaplan-Meier method.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Nasopharyngeal Carcinoma Patients Treated With Curative Radiotherapy

Sex eligibility

All sexes

Study type

Observational

Primary location

Taichung Veterans General Hospital

Taichung, 407, Taiwan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • previously untreated, biopsy-proven NPC
  • no distant metastasis

Exclusion criteria

  • incomplete record of history or treatment

Treatment and study plan

Patients without massive nasal bleeding

Other

No event of massive nasal bleeding after curative radiotherapy

Patients with massive nasal bleeding

Other

Any event of massive nasal bleeding after curative radiotherapy

Primary outcomes

  1. Massive Nasal Bleeding Rate

    Time frame: From date of radiotherapy until the date of first documented massive bleeding, assessed up to 360 months

    Massive Nasal Bleeding Rate among different characteristics. Massive Nasal Bleeding was defined as unique blood loss > 300 ml or recurrent blood losses > 100 ml.

Secondary outcomes

  1. Overall Survival

    Time frame: From date of radiotherapy until the date of last clinic visit or date of death from any cause, whichever came first, assessed up to 360 months

    Overall Survival

Sponsors and collaborators

Lead sponsor

Taichung Veterans General Hospital

Other

Registry information

Official study title

Massive Nasal Bleeding in Patients With Nasopharyngeal Carcinoma Received Curative Radiotherapy

Important dates

Study start
1994
Primary completion
2019
Study completion
2024
First posted
Apr 4, 2024
Registry last updated
Apr 4, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.